Vaidyanathan J - Search Results

1

Inclusion of Subjects who are Obese in Drug Development: Current Status and Opportunities.

Vaidyanathan J, Fletcher EP, Ramamoorthy A, Madabushi R, Burckart GJ. Vaidyanathan J, et al. J Clin Pharmacol. 2023 Nov;63 Suppl 2:S10-S17. doi: 10.1002/jcph.2327. J Clin Pharmacol. 2023. PMID: 37942907

2

Implications of obesity for drug therapy: limitations and challenges.

Jain R, Chung SM, Jain L, Khurana M, Lau SW, Lee JE, Vaidyanathan J, Zadezensky I, Choe S, Sahajwalla CG. Jain R, et al. Among authors: vaidyanathan j. Clin Pharmacol Ther. 2011 Jul;90(1):77-89. doi: 10.1038/clpt.2011.104. Epub 2011 Jun 1. Clin Pharmacol Ther. 2011. PMID: 21633345 Review.

3

Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization.

Khurana M, Vaidyanathan J, Marathe A, Mehrotra N, Sahajwalla CG, Zineh I, Jain L. Khurana M, et al. Among authors: vaidyanathan j. J Clin Pharmacol. 2015 Jun;55(6):647-56. doi: 10.1002/jcph.466. Epub 2015 Feb 16. J Clin Pharmacol. 2015. PMID: 25612234 Review.

4

Pediatric Drug Development Studies for Familial Hypercholesterolemia Submitted to the US Food and Drug Administration Between 2007 and 2020.

Park K, Vishnevetskaya K, Vaidyanathan J, Burckart GJ, Green DJ. Park K, et al. Among authors: vaidyanathan j. J Clin Pharmacol. 2022 Mar;62(3):397-408. doi: 10.1002/jcph.1973. Epub 2021 Oct 19. J Clin Pharmacol. 2022. PMID: 34562277 Review.

5

Leveraging Clinical Pharmacology Data to Assess Biosimilarity and Interchangeability of Insulin Products.

Vaidyanathan J, Wang YC, Tran D, Seo SK. Vaidyanathan J, et al. Clin Pharmacol Ther. 2023 Apr;113(4):794-802. doi: 10.1002/cpt.2731. Epub 2022 Sep 19. Clin Pharmacol Ther. 2023. PMID: 36052570 Review.

6

Predicting Food Effects on Oral Extended-Release Drug Products: A Retrospective Evaluation.

Zou P, Vaidyanathan J, Tran D, Raines K, Chatterjee P, Madabushi R, Seo SK. Zou P, et al. Among authors: vaidyanathan j. AAPS J. 2023 Mar 29;25(3):33. doi: 10.1208/s12248-023-00804-7. AAPS J. 2023. PMID: 36991196

7

Need for Representation of Pediatric Patients with Obesity in Clinical Trials.

Samuels S, Vaidyanathan J, Fletcher EP, Ramamoorthy A, Madabushi R, Burckart GJ. Samuels S, et al. Among authors: vaidyanathan j. Children (Basel). 2023 Sep 30;10(10):1640. doi: 10.3390/children10101640. Children (Basel). 2023. PMID: 37892303 Free PMC article.

8

Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products.

Eales B, Helal NA, Vattelana O, Kronfol MM, Fletcher EP, Wang YM, Burckart GJ, Vaidyanathan J, Seo SK, Nounou MI. Eales B, et al. Among authors: vaidyanathan j. J Clin Pharmacol. 2024 Aug 16. doi: 10.1002/jcph.6116. Online ahead of print. J Clin Pharmacol. 2024. PMID: 39149895

9

Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective.

Vaidyanathan J, Choe S, Sahajwalla CG. Vaidyanathan J, et al. J Pharm Sci. 2012 May;101(5):1659-71. doi: 10.1002/jps.23085. Epub 2012 Mar 1. J Pharm Sci. 2012. PMID: 22383396 Review.

10

Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1.

Vaidyanathan J, Yoshida K, Arya V, Zhang L. Vaidyanathan J, et al. J Clin Pharmacol. 2016 Jul;56 Suppl 7:S59-72. doi: 10.1002/jcph.723. J Clin Pharmacol. 2016. PMID: 27385179

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters